Long-term clinical outcome of intensity-modulated radiation therapy for locally advanced esophageal squamous cell carcinoma

被引:8
作者
Ge, Xiaolin [1 ]
Yang, Xi [1 ]
Lu, Xiaohu [2 ]
Wen, Wei [2 ]
Zhen, Fuxi [2 ]
Ye, Hongxun [3 ]
Zhu, Hongcheng [1 ]
Cao, Yuandong [1 ]
Zhang, Sheng [1 ]
Cheng, Hongyan [4 ]
Ma, Jianxin [5 ]
Yang, Baixia [6 ]
Dai, Shengbin [7 ]
Guo, Qing [7 ]
Cai, Jing
Sun, Xinchen [1 ]
机构
[1] Nanjing Med Univ, Affiliated Hosp 1, Dept Radiotherapy, Nanjing, Jiangsu, Peoples R China
[2] Nanjing Med Univ, Affiliated Hosp 1, Dept Cardiothorac Surg, Nanjing, Jiangsu, Peoples R China
[3] Taixing Peoples Hosp, Dept Radiotherapy, Taixing, Peoples R China
[4] Nanjing Med Univ, Affiliated Hosp 1, Dept Synthet Internal Med, Nanjing, Jiangsu, Peoples R China
[5] Bengbu Med Coll, Lianyungang Hosp, Peoples Hosp Lianyungang 2, Dept Radiotherapy, Lianyungang, Peoples R China
[6] Nantong Univ, Affiliated Tumor Hosp, Dept Radiotherapy, Nantong, Peoples R China
[7] Taizhou Peoples Hosp, Dept Radiotherapy, Taizhou, Peoples R China
来源
TUMORI JOURNAL | 2015年 / 101卷 / 02期
关键词
Esophageal squamous cell carcinoma; Intensity-modulated radiation therapy; Concurrent chemoradiotherapy; PROGNOSTIC-FACTORS; CANCER; RADIOTHERAPY; CHEMOTHERAPY; PACLITAXEL; CISPLATIN; PATTERNS; TRIAL;
D O I
10.5301/tj.5000234
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: This study evaluated the effectiveness and safety of intensity-modulated radiation therapy (IMRT) for locally advanced esophageal squamous cell carcinoma (ESCC). Methods: Between August 2009 and December 2011, 112 patients with pathologically confirmed ESCC treated with IMRT at Jiangsu Province People's Hospital and Nantong Tumor Hospital were included in a retrospective analysis. Patients received either IMRT alone (group A) or concurrent chemoradiotherapy (CRT) (group B). A radiation dose of 60-66 Gy administered in 30-33 fractions was delivered to the tumor. The patients in group B simultaneously received 2 cycles of cisplatin-based doublets with either 5-fluorouracil or taxotere. The Kaplan-Meier method was used to compute the survival time. Early and late toxicities were scored according to CTCAE v.3.0. Results: The response rate of group B (91.07%) was not significantly greater than that of group A (89.29%) (chi(2) = 0.10, p = 0.75). The 1- and 3-year survival rates of group B (87.5% and 57.14%, respectively) were greater than those of group A (69.64% and 37.50%, respectively). The difference in overall survival was statistically significant between groups A and B (chi(2) = 5.30, p = 0.02;chi(2) = 4.33, p = 0.04). Hematological toxicity, gastrointestinal toxicity, and treatment-related esophagitis were significantly higher in group B than group A (16.07% vs. 33.93%, p = 0.04; 10.71% vs. 26.79%, p = 0.03; 19.64% vs. 44.64%, p = 0.01). However, intergroup differences in terms of late toxicity were not significant. Conclusions: IMRT was a practical and feasible technique to treat ESCC. Concurrent CRT could increase local tumor control and long-term survival. The CRT regimen was associated with a higher incidence of acute gastrointestinal and hematological toxicity.
引用
收藏
页码:168 / 173
页数:6
相关论文
共 26 条
[1]   Three-field lymph node dissection for squamous cell and adenocarcinoma of the esophagus [J].
Altorki, N ;
Kent, M ;
Ferrara, C ;
Port, J .
ANNALS OF SURGERY, 2002, 236 (02) :177-183
[2]   ESOPHAGEAL SQUAMOUS-CELL CARCINOMA .1. A CRITICAL-REVIEW OF SURGERY [J].
EARLAM, R ;
CUNHAMELO, JR .
BRITISH JOURNAL OF SURGERY, 1980, 67 (06) :381-390
[3]   Medical progress - Esophageal cancer [J].
Enzinger, PC ;
Mayer, RJ .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (23) :2241-2252
[4]   Improving radiotherapy planning, delivery accuracy, and normal tissue sparing using cutting edge technologies [J].
Glide-Hurst, Carri K. ;
Chetty, Indrin J. .
JOURNAL OF THORACIC DISEASE, 2014, 6 (04) :303-318
[5]   COMBINED CHEMOTHERAPY AND RADIOTHERAPY COMPARED WITH RADIOTHERAPY ALONE IN PATIENTS WITH CANCER OF THE ESOPHAGUS [J].
HERSKOVIC, A ;
MARTZ, K ;
ALSARRAF, M ;
LEICHMAN, L ;
BRINDLE, J ;
VAITKEVICIUS, V ;
COOPER, J ;
BYHARDT, R ;
DAVIS, L ;
EMAMI, B .
NEW ENGLAND JOURNAL OF MEDICINE, 1992, 326 (24) :1593-1598
[6]   Definitive Chemoradiation Therapy With Docetaxel, Cisplatin, and 5-Fluorouracil (DCF-R) in Advanced Esophageal Cancer: A Phase 2 Trial (KDOG 0501-P2) [J].
Higuchi, Katsuhiko ;
Komori, Shouko ;
Tanabe, Satoshi ;
Katada, Chikatoshi ;
Azuma, Mizutomo ;
Ishiyama, Hiromichi ;
Sasaki, Tohru ;
Ishido, Kenji ;
Katada, Natsuya ;
Hayakawa, Kazushige ;
Koizumi, Wasaburo .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 89 (04) :872-879
[7]   Long-term toxicity after definitive chemoradiotherapy for squamous cell carcinoma of the thoracic esophagus [J].
Ishikura, S ;
Nihei, K ;
Ohtsu, A ;
Boku, N ;
Hironaka, S ;
Mera, K ;
Muto, M ;
Ogino, TG ;
Yoshida, S .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (14) :2697-2702
[8]   Cancer statistics, 2008 [J].
Jemal, Ahmedin ;
Siegel, Rebecca ;
Ward, Elizabeth ;
Hao, Yongping ;
Xu, Jiaquan ;
Murray, Taylor ;
Thun, Michael J. .
CA-A CANCER JOURNAL FOR CLINICIANS, 2008, 58 (02) :71-96
[9]   The role of taxanes in the management of gastroesphageal cancer [J].
Jimenez, Paola ;
Pathak, Aditya ;
Phan, Alexandria T. .
JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2011, 2 (04) :240-249
[10]   Local failure patterns for patients with nasopharyngeal carcinoma after intensity-modulated radiotherapy [J].
Li, Jia-xin ;
Huang, Shao-min ;
Jiang, Xin-hua ;
Ouyang, Bin ;
Han, Fei ;
Liu, Shuai ;
Wen, Bi-xiu ;
Lu, Tai-xiang .
RADIATION ONCOLOGY, 2014, 9